Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or ...

This Friday, local man David Tasker will complete the last of his ten challenges to raise money for amyloidosis research and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

(12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of ...